Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?

It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan market at stake, there's likely more than enough room for multiple major competitors to find a home.